Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
nimotuzumab + adebrelimab + albumin-bound paclitaxel + carboplatin
- Development stage
- Unknown
- Lead developer
- Hengrui Therapeutics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
This combination therapy is being evaluated in a Phase Ib/II clinical trial led by Fudan University for the treatment of recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) in patients who are ineligible for high-dose cisplatin. The regimen consists of nimotuzumab, a humanized monoclonal antibody targeting the epidermal growth factor receptor (EGFR); adebrelimab, a humanized monoclonal antibody targeting programmed death-ligand 1 (PD-L1); and a chemotherapy backbone of albumin-bound paclitaxel and carboplatin. By combining EGFR inhibition, immune checkpoint blockade, and cytotoxic chemotherapy, the regimen aims to provide a synergistic anti-tumor effect while offering a more tolerable alternative for cisplatin-ineligible patients.
- Other names
- Nimotuzumab + Adebrelimab + ChemotherapyNimotuzumab + Adebrelimab + nab-paclitaxel + carboplatin
02
Targets
DNAEGFR (Epidermal growth factor receptor)CD274 (Programmed cell death protein 1 ligand 1)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on nimotuzumab + adebrelimab + albumin-bound paclitaxel + carboplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on nimotuzumab + adebrelimab + albumin-bound paclitaxel + carboplatin.